Loading...
Please wait, while we are loading the content...
Similar Documents
Mitochondria-targeted spin-labelled luminescent iridium anticancer complexes† †Electronic supplementary information (ESI) available. CCDC 1522104. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c7sc03216a
| Content Provider | Semantic Scholar |
|---|---|
| Author | Venkatesh, V. Berrocal-Martin, Raul Wedge, Christopher J. Romero-Canelón, Isolda Sanchez-Cano, Carlos Song, Ji-Inn Coverdale, James P. C. Zhang, Pingyu Clarkson, Guy J. Habtemariam, Abraha Magennis, Steven W. Deeth, Robert J. Sadler, Peter J. |
| Copyright Year | 2017 |
| Abstract | Mitochondria generate energy but malfunction in many cancer cells, hence targeting mitochondrial metabolism is a promising approach for cancer therapy. Here we have designed cyclometallated iridium(iii) complexes, containing one TEMPO (2,2,6,6-tetramethylpiperidine-1-oxyl) spin label [C43H43N6O2Ir1·PF6]˙ (Ir-TEMPO1) and two TEMPO spin labels [C52H58N8O4Ir1·PF6]˙ (Ir-TEMPO2). Electron paramagnetic resonance (EPR) spectroscopy revealed spin-spin interactions between the TEMPO units in Ir-TEMPO2. Both Ir-TEMPO1 and Ir-TEMPO2 showed bright luminescence with long lifetimes (ca. 35-160 ns); while Ir-TEMPO1 displayed monoexponential decay kinetics, the biexponential decays measured for Ir-TEMPO2 indicated the presence of more than one energetically-accessible conformation. This observation was further supported by density functional theory (DFT) calculations. The antiproliferative activity of Ir-TEMPO2 towards a range of cancer cells was much greater than that of Ir-TEMPO1, and also the antioxidant activity of Ir-TEMPO2 is much higher against A2780 ovarian cancer cells when compared with Ir-TEMPO1. Most notably Ir-TEMPO2 was particularly potent towards PC3 human prostate cancer cells (IC50 = 0.53 μM), being ca. 8× more active than the clinical drug cisplatin, and ca. 15× more selective towards cancer cells versus normal cells. Confocal microscopy showed that both Ir-TEMPO1 and Ir-TEMPO2 localise in the mitochondria of cancer cells. |
| Starting Page | 8271 |
| Ending Page | 8278 |
| Page Count | 8 |
| File Format | PDF HTM / HTML |
| DOI | 10.1039/c7sc03216a |
| PubMed reference number | 29568475 |
| Journal | Medline |
| Volume Number | 8 |
| Alternate Webpage(s) | https://research.birmingham.ac.uk/portal/files/48557047/C7SC03216A.pdf |
| Alternate Webpage(s) | http://eprints.hud.ac.uk/id/eprint/34086/1/c7sc03216a.pdf |
| Alternate Webpage(s) | http://eprints.gla.ac.uk/150228/7/150228.pdf |
| Alternate Webpage(s) | http://wrap.warwick.ac.uk/100785/1/WRAP-mitochondria-targeted%20spin-labelled-luminescent-iridium-anticancer-complexes-Sadler-2017.pdf |
| Alternate Webpage(s) | https://doi.org/10.1039/c7sc03216a |
| Journal | Chemical science |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |